Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Authors
Discussion
Loading...
Member takes
Implication
Phase 1b trial demonstrates increased T cell infiltration and improved response in advanced melanoma, suggesting oncolytic virotherapy enhances anti-PD-1 immunotherapy efficacy.
Key Points
- To evaluate the impact of talimogene laherparepvec on cytotoxic T cell infiltration and assess the therapeutic efficacy of subsequent pembrolizumab combination therapy.
- Conducted a phase 1b clinical trial enrolling 21 patients with advanced melanoma.
- Administered talimogene laherparepvec followed by combination treatment with the anti-PD-1 antibody pembrolizumab.
- Confirmed objective response rate was 62%, with a complete response rate of 33% by immune-related response criteria; no dose-limiting toxicities occurred.
- Responding patients exhibited elevated CD8+ T cells, PD-L1 protein expression, and IFN-γ gene expression following virotherapy, which occurred independent of baseline immune status.
Cite This Study
Ribas et al. (2017) studied this question.